Phio Pharmaceuticals Corporation (PHIO) News

LMFAO🤣

Me and you know how to make coin, comes easy for us PHIO

HOLY SMACK A RONNIES THE SANFRISCO TREAT PHIO GGGGGGGGGGOOO PHIO

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
Newsfile Corp.
Newsfile Corp
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research Session

Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced that a podium presentation addressing its lead product candidate, PH-762, was given in the Academy's Late-Breaking Research session. The Late-Breaking Research session includes oral presentations of the top-scoring abstracts that address common and complex dermatological conditions.

Mary Spellman, MD, FAAD, presented "PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: Interim Results from an Ongoing Study of INTASYL PH-762" which provided details on the design and progress of Phio's ongoing open-label Phase 1b clinical study (NCT 06014086), to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. Stages 1 and 2 cSCC represent 77% of all new cSCC annually.

Recent data showed that, of the four patients who have completed treatment in the second dose cohort, two patients with cutaneous squamous cell carcinoma achieved a complete response (100% pathological cure) while a third patient with squamous cell carcinoma achieved a partial response (90% pathological cure). The fourth patient in this cohort exhibited stable disease, having not progressed.

The study recently fulfilled the required enrollment for safety in its third dose cohort. Initiation of screening of the fourth dose cohort is planned for early April.

"We are excited to share our progress in this trial with the dermatology community," said Mary Spellman M.D., Phio's acting Chief Medical Officer. "We believe that this immuno-oncology therapy may offer patients meaningful clinical benefit, while minimizing surgical interventions."

WHATS THE RANGE? 40 CENTS? PHIO

Cool on it PHIO

Spuds! Absolutely! Nobody pays much attention to this when its going down but they chase it every time it pops. This is a great one short-term and long🤭

I always like your analytics. Just wait, many will come back strong!😁

YA BIG TIME , RUNNING AROUND NAKED IN THE SNOW , WANT A PICTURE? PHIO

20/30 cents coming PHIO MEOW

phio is the bomb

This is another med sector of over 450 issues
https://www.barchart.com/stocks/quotes/CRSP/competitors?quoteSectors=-283G&viewName=main&orderBy=weightedAlpha&orderDir=desc
The burning question going forward is have a lot of stocks reached absolute bottom?

The broader med sectors have been in a bear market for months
This link to a Barchart webpage has a sector chart for 147:issues, including PHIO
https://www.barchart.com/stocks/quotes/PSTV/competitors?quoteSectors=-MEDR&viewName=main&orderBy=weightedAlpha&orderDir=desc
Provides ample evidence

Way oversold! All it will take is one fairly meaty PR and BANG ZOOM!😷

PHIO under $2

I think PHIO is due for a pop! She has a minimal public float!😍😇

Nice PHIO

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
Newsfile Corp.
Newsfile Corp
Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it has fulfilled the required enrollment for safety in its third dose cohort in its Phase 1b dose escalating clinical study for their lead compound PH-762. The company plans to initiate screening of the fourth dose cohort in early April.

Phio's Phase 1b study (NCT 06014086) is a multi-center, dose-escalating clinical trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This study assesses the tumor response and determines the recommended dose for further study of PH-762.

"We are excited with the rapid completion of enrollment of the third safety cohort," said Robert Bitterman, CEO of Phio Pharmaceuticals. "We look forward to rapidly advancing the study to bring an innovative, alternative treatment option to patients with skin carcinomas."

funny anecdote
this one gave ALNY the schvitz in 2010 because of the IP around RNAi conjugation.
Needless to say thats not the case anymore.
Just goes to show they know exxactly what they are doing with this scam.

OT: I know you are bro🤑 and you need to keep a close tab on RNAZ she is dropping like a rock today. Anything under $ 5.00 is child's play!

ya I'm in just kidding around we are solid , got a boat load of money

Do you want😍 to join me?😋😇😁

1.65 lol u clown sell dip douche

$1.44 new 52-week low. Bought $1.47 on my double down. 😇

Currently, $1.57 nearing its 52-week low of $1.53. Should she drop under $1.50 I'm doubling down.😷

Grabbed $1.79♥️

Very nice indeed! I am still holding that other half from the last time it ran. This Company I like long term as well🤩

$2.20 now ..Picked up $1.90s yesterday and flipped out at $2.60s this morning. Going to grab some more on the new dump for next flip $1.90- 2.20 should be good buying zone today 

Let it get sloppy like last time. 🤣

S-1 Does the forecast call for pain...

Pros: If PHIO demonstrates strong progress in its clinical trials, communicates a clear and effective use of proceeds, and generates positive clinical and financial milestones, the additional 5.9 million shares is a reasonable trade-off for long-term growth.

Cons: If there’s limited progress (no reason to believe there will be with the recent news) delays, or ambiguity about the company’s ability to monetize its pipeline, the market may view the dilution as detrimental, which will be bad, very, very bad indeed.

When will the warrants expire??

Series E Warrants: Exercisable until December 2029 @ $2.51
Series F Warrants: Exercisable until December 2029 @ 2.00
Series G, H, and I Warrants: Exercisable until January 2027 $3.00
Warrants must be exercised voluntarily, and holders typically do so when the market price exceeds the warrant exercise price.

This may get sloppy, so hold on.

PHIO: We are all LONG-GONE with our PROFITS, Dude!!! (Thank you, PHIO company!!!!)

lol told you new offering 

PHIO: See ME, below, workin' on that $10.00, right now!!!

"PLEASE, Oh Lord, give me $10.00 even on PHIO today, & I'll donate 50% of my profits to THE STARVATION ARMY, and SAINT JUDE'S CHILDREN'S REFORMATORY!!"

Yea buddy great call on your part here! I flipped out 1/2 of my position at the same price as you!♥️

hope you see that $10 bro 

PHIO: Heck, now look at what you just made me do with your post, Dude!! (That's me LIVE, below, right NOW via my San Diego KITCHEN-CAM!!!)

Company has multiple Form 424B5 - Prospectus [Rule 424(b)(5)]
Last few months

it a dilution pos bro offering...offering 

Mostly out $4.30s thanks for tips..SENS could reclaim $2s on the 3 year has some work. TNXP has a nice bottom chart

PHIO: Ten bucks easy today. (I will kick-back now, & relax.)

PHIO: Don't think they'll Halt it --- volume still very low.

Took some off $3.80s before the halt comes 

PHIO: And it did just THAT!!

One step at a time says humankind. Blow those $3.29s we rocket launch 🚀 to Jupiter 

PHIO: They had GREAT news few days ago!! (Rarely hear anything great about CANCER.)

PHIO: Could have $5.00 here today.

Small offerings with excellent news are ok $3.14

The offering was small. IMHO I think many got trapped on the 400% run and dumped for a loss. 😷

$2.72 gone green offering absorbed now. Let's see what happens next $6- $8 targets 

Beautiful!🤩